Adults with class II to III obesity may have increased cardiac outcomes
Click Here to Manage Email Alerts
Key takeaways:
- Researchers found class II to III obesity was linked to cardiovascular events in adults.
- Class II to III obesity was not tied to kidney outcomes in multivariable adjusted analysis.
Adults with class II to III obesity may have an increased risk for poor cardiac outcomes but not kidney risk after adjusting for potential confounders, according to multicenter data.
“Obesity is an increasingly prevalent risk factor for the development and progression of both chronic kidney disease (CKD) and cardiovascular disease (CVD),” Evan M. Zeitler, MD, of the University of North Carolina at Chapel Hill nephrology and hypertension division, wrote with colleagues. “Patients with glomerular disease [GN] are also at higher risk of CKD and CVD than the general population but whether obesity contributes to this increased risk is not known.”
Researchers examined 2,301 patients (1,548 adults and 753 children) with glomerular kidney disease in the Cure Glomerulonephropathy Network (CureGN) and were aged at least 5 years at enrollment.
In the prospective, observational study, patients were categorized into adult BMI groups and pediatric BMI percentiles. The incidence of the primary kidney endpoint was 90.8 per 1,000 person-years in adults compared with 58 among normal weight comparators.
Primary outcomes were a kidney composite of 40% eGFR decline or kidney failure, and a cardiovascular composite, including myocardial infarction, stroke, heart failure or death.
In the univariable analysis, class II to III obesity was associated with the primary kidney outcome in adults compared with people in the healthy weight groups, according to the results. However, in the multivariable adjusted analysis, class II to III obesity was not significantly tied to kidney outcomes in adults when controlling for baseline eGFR and proteinuria.
Zeitler and researchers found adults with class II to III obesity had a greater incidence of cardiovascular events, with 19.7 cardiovascular events per 1,000 person-years, and greater cardiovascular risk.
“This study contributes to the evidence that obesity adversely affects the clinical course of patients with GN, highlighting the need for further research into mechanisms underlying this association and interventions targeted at reducing its impact,” they wrote.
“Taking advantage of standardized pathology scoring and existing biosamples within CureGN may help not only to clarify the interaction between obesity and glomerular disease, but with the progression of CKD generally.”
Collapse
Click Here to Manage Email Alerts